Search results for "VITRO"

showing 10 items of 2786 documents

Coupling of the antiviral agent zidovudine to polyaspartamide and in vitro drug release studies.

1998

A macromolecular prodrug of the known antiretroviral agent zidovudine and alpha, beta-poly(N-2-hydroxyethyl)-DL-aspartamide (PHEA) was synthesized. A succinic spacer was present between the polymer and the drug, and 1,1'-carbonyldiimidazole was used as the coupling agent. In vitro drug release studies at pH 1.1, 5.5 and 7.4 indicated that limited amounts of intact drug were released from the conjugate. At pH 1.1 and 7.4 succinylzidovudine was released, and this was hydrolysed to give free zidovudine. In the presence of alpha-chymotrypsin, zidovudine was released preferentially in comparison with the succinyl derivative. The amounts of released zidovudine and succinylzidovudine were greater …

DrugActive ingredientDrug CarriersChemistryAnti-HIV Agentsmedia_common.quotation_subjectHydrolysisPharmaceutical ScienceProdrugPharmacologyHydrogen-Ion ConcentrationIn Vitro TechniquesIn vitroZidovudinemedicineLiberationChymotrypsinHumansProdrugsDrug carrierPeptidesZidovudinemedia_commonmedicine.drugConjugateJournal of controlled release : official journal of the Controlled Release Society
researchProduct

Flupirtine protects both neuronal cells and lymphocytes against induced apoptosis in vitro: Implications for treatment of AIDS patients

1999

In the present study we demonstrate that flupirtine, an already clinically used, centrally acting, non-opiate analgesic agent, protects rat cortical neurons against HIV-gp120 induced apoptotic cell death. The drug was active at concentrations between 1 and 10 microg/ml. Furthermore we show inhibition of in vitro induced apoptosis in human blood mononuclear cells, using flupirtine. Induced apoptosis in peripheral blood mononuclear cells from healthy individuals and HIV-1 infected patients was reduced to approximately 50% after in vitro preincubation with flupirtine at concentrations between 0.1 and 10 microg/ml. The anti-apoptotic effect of flupirtine was restricted to CD3+ lymphocytes and i…

DrugAids patientsbiologybusiness.industryCD3media_common.quotation_subjectAnalgesicCell BiologyPharmacologyPeripheral blood mononuclear cellIn vitroApoptosisbiology.proteinMedicineFlupirtinebusinessMolecular Biologymedia_commonmedicine.drugCell Death & Differentiation
researchProduct

In vitro activity of fluconazole, voriconazole and caspofungin against clinical yeast isolates.

2007

Predicting the clinical outcome of a systemic mycosis is often a difficult task, especially when microbiological resistance is one of the factors contributing to therapeutic failure. Some of these factors are host-related--e.g. immune state, site and severity of infection, poor compliance to therapy--while others are associated with the drug's characteristics--e.g. dosage, type of compound (fungistatic/fungicidal), pharmacokinetic properties and drug-drug interactions. In the last few years, clinicians have been confronted with the problem of selecting the most appropriate antifungal therapy for systemic infections and have highlighted the need for a reliable method to assay the in vitro su…

DrugAntifungal AgentsSystemic mycosismedia_common.quotation_subjectMicrobial Sensitivity TestsBiologyPharmacologyPeptides Cyclicchemistry.chemical_compoundEchinocandinsLipopeptidesPharmacokineticsCaspofunginDrug Resistance FungalmedicineHumansPharmacology (medical)Fluconazolemedia_commonCandidaPharmacologyVoriconazoleTriazolesYeastIn vitroInfectious DiseasesPyrimidinesOncologychemistryVoriconazoleCaspofunginFluconazolemedicine.drugJournal of chemotherapy (Florence, Italy)
researchProduct

Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties

2010

Abstract Artemisinins are plant products with a wide range of medicinal applications. Most prominently, artesunate is a well tolerated and effective drug for treating malaria, but is also active against several protozoal and schistosomal infections, and additionally exhibits anti-angiogenic, anti-tumorigenic and anti-viral properties. The array of activities of the artemisinins, and the recent emergence of malaria resistance to artesunate, prompted us to synthesize and evaluate several novel artemisinin-like derivatives. Sixteen distinct derivatives were therefore synthesized and the in vitro cytotoxic effects of each were tested with different cell lines. The in vivo anti-angiogenic proper…

DrugArtemisininsSwinemedia_common.quotation_subjectmalariaArtemisia annuaAngiogenesis InhibitorsDrug resistanceArtemisia annuaP-glycoproteinPharmacologychemotherapyStructure-Activity Relationshipchemistry.chemical_compoundIn vivoparasitic diseasesmedicineAnimalscancerArtemisininCells CulturedZebrafishCell Proliferationmedia_commondrug resistancebiologyPlant ExtractsArticlesCell BiologyFlow Cytometrybiology.organism_classificationArtemisininsIn vitrochemistryArtesunateMolecular Medicinemedicine.drugJournal of Cellular and Molecular Medicine
researchProduct

Rapamycin-Loaded Polymeric Nanoparticles as an Advanced Formulation for Macrophage Targeting in Atherosclerosis

2021

Recently, rapamycin (Rapa) represents a potential drug treatment to induce regression of atherosclerotic plaques

DrugBiodistributionmedia_common.quotation_subjectPharmaceutical ScienceExcipientNanoparticlelcsh:RS1-44102 engineering and technologyPharmaceutical formulationArticlelcsh:Pharmacy and materia medica03 medical and health scienceschemistry.chemical_compoundPhosphatidylcholinemedicine030304 developmental biologymedia_commonKOdia-PC0303 health sciencesrapamycin (Rapa)technology industry and agriculture021001 nanoscience & nanotechnologyIn vitromacrophage targetingpolymeric nanoparticleschemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoPolycaprolactoneBiophysicsatherosclerosis0210 nano-technologymedicine.drugPharmaceutics
researchProduct

In vitro and in vivo characterization of a new organic nitrate hybrid drug covalently bound to pioglitazone.

2014

<b><i>Background/Aims:</i></b> Organic nitrates represent a group of nitrovasodilators that are clinically used for the treatment of ischemic heart disease. The new compound CLC-3000 is an aminoethyl nitrate (AEN) derivative of pioglitazone, a thiazolidinedione antidiabetic agent combining the peroxisome proliferator-activated receptor γ agonist activity of pioglitazone with the NO-donating activity of the nitrate moiety. <b><i>Methods:</i></b> In vitro and in vivo characterization was performed by isometric tension recording, platelet function, bleeding time and detection of oxidative stress. <b><i>Results:</i></…

DrugBlood PlateletsMaleBleeding TimePlatelet Aggregationmedia_common.quotation_subjectVasodilator Agentsmedicine.disease_causeMitochondria Heartchemistry.chemical_compoundNitrateFibrinolytic AgentsIn vivomedicineAnimalsHumansHypoglycemic AgentsRats WistarAortamedia_commonPharmacologyNitratesPioglitazoneChemistryGeneral MedicineReactive Nitrogen SpeciesIn vitroOrganic nitratesMice Inbred C57BLVasodilationBiochemistryCovalent bondVasoconstrictionThiazolidinedionesReactive Oxygen SpeciesPioglitazoneOxidative stressmedicine.drugPharmacology
researchProduct

A brief guide to performing pharmacological studies in vitro: Reflections from the EORTC-PAMM Course “Preclinical and Early-phase Clinical Pharmacolo…

2019

One aim of cell-based in vitro assays is to identify the best drug candidate to develop using the best tumor cell model. This is challenging in every anticancer drug discovery process. Briefly, we summarize the parameters to be taken into account when performing in vitro cell assays, in order to obtain reliable and reproducible results, which was fundamentally discussed by lecturers at the educational course on preclinical and early-phase clinical pharmacology studies, at the 40th Winter Meeting of the Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. Moreover, specific cellular sensitivity tests are described. In addition to mono…

DrugCancer ResearchClinical pharmacologybusiness.industrymedia_common.quotation_subjectIn vitro toxicologyTumor cellsGeneral MedicineComputational biologyAnticancer drugIn vitrolaw.invention03 medical and health sciences0302 clinical medicineOncologylawIn vivo030220 oncology & carcinogenesisMedicineEarly phasebusinessmedia_commonAnticancer Research
researchProduct

Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells

2014

Background: In hepatocellular carcinoma (HCC), different signaling pathways are de-regulated, and among them, the expression of the epidermal growth factor receptor (EGFR). Tyrphostin AG-1478 is a lipophilic low molecular weight inhibitor of EGFR, preferentially acting on liver tumor cells. In order to overcome its poor drug solubility and thus improving its anticancer activity, it was entrapped into nanostructured lipid carriers (NLC) by using safe ingredients for parenteral delivery. Results: Nanostructured lipid carriers (NLC) carrying tyrphostin AG-1478 were prepared by using the nanoprecipitation method and different matrix compositions. The best system in terms of mean size, PDI, zeta…

DrugCarcinoma HepatocellularHepatocellular carcinomamedia_common.quotation_subjectBiomedical EngineeringMedicine (miscellaneous)Pharmaceutical ScienceAntineoplastic AgentsBioengineeringPharmacologyApplied Microbiology and BiotechnologyCell Line TumormedicineHumansEpidermal growth factor receptorNanostructured lipid carriers Tyrphostin AG-1478 Drug release Hepatocellular carcinoma EGFR inhibitor.media_commonEGFR inhibitorsDrug CarriersNanostructured lipid carriersbiologyChemistryResearchLiver NeoplasmsCorrectionDrug releaseTyrphostinsmedicine.diseaseLipidsTyrphostin AG-1478Molecular medicineIn vitroNanostructuresErbB ReceptorsEGFR inhibitorLiverSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoHepatocellular carcinomaDrug deliveryQuinazolinesbiology.proteinMolecular MedicineDrug carrier
researchProduct

Controlled transdermal iontophoresis by ion-exchange fiber

2000

The objective of this study was to assess the transdermal delivery of drugs using iontophoresis with cation- and anion-exchange fibers as controlled drug delivery vehicles. Complexation of charged model drugs with the ion-exchange fibers was studied as a method to achieve controlled transdermal drug delivery. Drug release from the cation-exchange fiber into a physiological saline was dependent on the lipophilicity of the drug. The release rates of lipophilic tacrine and propranolol were significantly slower than that of hydrophilic nadolol. Permeation of tacrine across the skin was directly related to the iontophoretic current density and drug concentration used. Anion-exchange fiber was te…

DrugChemical PhenomenaSkin Absorptionmedia_common.quotation_subjectPharmaceutical Science02 engineering and technologyIn Vitro TechniquesPharmacologyAdministration Cutaneous030226 pharmacology & pharmacyDosage form03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHumansFiberElectrodesSodium salicylateTransdermalmedia_commonMineral FibersActive ingredientChromatographyIontophoresisChemistry PhysicalIontophoresisModels Theoretical021001 nanoscience & nanotechnologyIon ExchangechemistryDrug deliveryTacrine0210 nano-technologyAlgorithmsJournal of Controlled Release
researchProduct

Potential of biopartitioning micellar chromatography as an in vitro technique for predicting drug penetration across the blood–brain barrier

2004

The blood-brain barrier (BBB) is considered to be the main barrier to drug transport into the central nervous system (CNS). The BBB restricts the passive diffusion of many drugs from blood to brain. The ease with which any particular drug diffuses across the BBB is determined largely by the molecular features of drugs, and it is therefore possible to predict the BBB permeability of a drug from its molecular structure. Biopartitioning micellar chromatography (BMC), a mode of micellar liquid chromatography that uses micellar mobile phases of Brij35 in adequate experimental conditions, can be useful in mimicking the drug partitioning process into biological systems. Retention in BMC depends on…

DrugChromatographyChemistrymedia_common.quotation_subjectClinical BiochemistryCell BiologyGeneral MedicinePenetration (firestop)In Vitro TechniquesModels TheoreticalBlood–brain barrierDrug penetrationBiochemistryIn vitroAnalytical ChemistryPartition coefficientmedicine.anatomical_structureBlood-Brain BarrierMicellar liquid chromatographymedicineRegression AnalysisChromatography Liquidmedia_commonDrug transportJournal of Chromatography B
researchProduct